Shigella Sonnei 53G Human Infection Study in Kenyan Adults
Condition: Shigellosis Interventions: Biological: Shigella sonnei 53G; Drug: Ciprofloxacin 500 mg Sponsors: University of Oxford; KEMRI-Wellcome Trust Collaborative Research Program; KEMRI United States Army Medical Research Directorate-Kenya; Walter Reed Army Institute of Research (WRAIR); Naval Medical Research Center; PATH; Johns Hopkins University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials